Two-year treatment of alzheimer's disease with eptastigmine

F. Piccoli, R. M. Ruggien, M. Oliveri, B. P. Imbimbo

Research output: Contribution to journalArticle

Abstract

The long term effectiveness of choiinesterase inhibitors in Alzheimer's disease (AD) is a matter of controversy To evaluate the potential long-term effects of eptastigmme, a new choiinesterase inhibitor, we evaluated data obtained from the open label extension phase of a 25-week, double-blind, placebo-controlled multicenter study in 320 patients with probable AD. In the double-blind phase of the study, patients received placebo t.i.d. (n=106) or eptastigmine 10 mg t.i.d. (n=105) or eptastigmine 15 mg t i.d. (n=109). At the end of the double-blind phase, patients receiving 15 mg t.i.d. performed significantly better than placebo-treated patients on the ADAS-Cog scale In the open label extension phase, patients received eptastigmine 10 mg t.i.d. Twenty-six patients (lOmales and 16 females) with a mean MMSE score of 20 9 and a mean age of 68 years at baseline, completed two years of treatment. The drug was well tolerated At the end of the two year-treatment they showed a worsening of 76 points on ADAS-Cog, 37 points on MMSE and 2.2 points on Instrumental Activities of Daily Living scale Patients with mild to moderate AD treated with placebo are expected to have a worsening of approximately 7.0 points per year on ADAS-Cog, 3.8 points on MMSE and 3.5 points on IADL Compared to published deterioration rates, patients treated with eptastigmine for two years had a benefit of 6.4 points on ADAS-Cog, 39 points on MMSE and 4.8 points on IADL These benefits translate to about one year difference between eptastigmme-treated patients and placebo-treated patients Our data support the view that AD patients derive long-term benefit from eptastigmine.

Original languageEnglish
Pages (from-to)29
Number of pages1
JournalItalian Journal of Neurological Sciences
Volume18
Issue number4
Publication statusPublished - 1997

Fingerprint

Alzheimer Disease
Placebos
Therapeutics
physostigmine heptyl
Activities of Daily Living
Double-Blind Method
Multicenter Studies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Piccoli, F., Ruggien, R. M., Oliveri, M., & Imbimbo, B. P. (1997). Two-year treatment of alzheimer's disease with eptastigmine. Italian Journal of Neurological Sciences, 18(4), 29.

Two-year treatment of alzheimer's disease with eptastigmine. / Piccoli, F.; Ruggien, R. M.; Oliveri, M.; Imbimbo, B. P.

In: Italian Journal of Neurological Sciences, Vol. 18, No. 4, 1997, p. 29.

Research output: Contribution to journalArticle

Piccoli, F, Ruggien, RM, Oliveri, M & Imbimbo, BP 1997, 'Two-year treatment of alzheimer's disease with eptastigmine', Italian Journal of Neurological Sciences, vol. 18, no. 4, pp. 29.
Piccoli, F. ; Ruggien, R. M. ; Oliveri, M. ; Imbimbo, B. P. / Two-year treatment of alzheimer's disease with eptastigmine. In: Italian Journal of Neurological Sciences. 1997 ; Vol. 18, No. 4. pp. 29.
@article{7facdea146b641658ef09aac43886745,
title = "Two-year treatment of alzheimer's disease with eptastigmine",
abstract = "The long term effectiveness of choiinesterase inhibitors in Alzheimer's disease (AD) is a matter of controversy To evaluate the potential long-term effects of eptastigmme, a new choiinesterase inhibitor, we evaluated data obtained from the open label extension phase of a 25-week, double-blind, placebo-controlled multicenter study in 320 patients with probable AD. In the double-blind phase of the study, patients received placebo t.i.d. (n=106) or eptastigmine 10 mg t.i.d. (n=105) or eptastigmine 15 mg t i.d. (n=109). At the end of the double-blind phase, patients receiving 15 mg t.i.d. performed significantly better than placebo-treated patients on the ADAS-Cog scale In the open label extension phase, patients received eptastigmine 10 mg t.i.d. Twenty-six patients (lOmales and 16 females) with a mean MMSE score of 20 9 and a mean age of 68 years at baseline, completed two years of treatment. The drug was well tolerated At the end of the two year-treatment they showed a worsening of 76 points on ADAS-Cog, 37 points on MMSE and 2.2 points on Instrumental Activities of Daily Living scale Patients with mild to moderate AD treated with placebo are expected to have a worsening of approximately 7.0 points per year on ADAS-Cog, 3.8 points on MMSE and 3.5 points on IADL Compared to published deterioration rates, patients treated with eptastigmine for two years had a benefit of 6.4 points on ADAS-Cog, 39 points on MMSE and 4.8 points on IADL These benefits translate to about one year difference between eptastigmme-treated patients and placebo-treated patients Our data support the view that AD patients derive long-term benefit from eptastigmine.",
author = "F. Piccoli and Ruggien, {R. M.} and M. Oliveri and Imbimbo, {B. P.}",
year = "1997",
language = "English",
volume = "18",
pages = "29",
journal = "Italian Journal of Neurological Sciences",
issn = "0392-0461",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Two-year treatment of alzheimer's disease with eptastigmine

AU - Piccoli, F.

AU - Ruggien, R. M.

AU - Oliveri, M.

AU - Imbimbo, B. P.

PY - 1997

Y1 - 1997

N2 - The long term effectiveness of choiinesterase inhibitors in Alzheimer's disease (AD) is a matter of controversy To evaluate the potential long-term effects of eptastigmme, a new choiinesterase inhibitor, we evaluated data obtained from the open label extension phase of a 25-week, double-blind, placebo-controlled multicenter study in 320 patients with probable AD. In the double-blind phase of the study, patients received placebo t.i.d. (n=106) or eptastigmine 10 mg t.i.d. (n=105) or eptastigmine 15 mg t i.d. (n=109). At the end of the double-blind phase, patients receiving 15 mg t.i.d. performed significantly better than placebo-treated patients on the ADAS-Cog scale In the open label extension phase, patients received eptastigmine 10 mg t.i.d. Twenty-six patients (lOmales and 16 females) with a mean MMSE score of 20 9 and a mean age of 68 years at baseline, completed two years of treatment. The drug was well tolerated At the end of the two year-treatment they showed a worsening of 76 points on ADAS-Cog, 37 points on MMSE and 2.2 points on Instrumental Activities of Daily Living scale Patients with mild to moderate AD treated with placebo are expected to have a worsening of approximately 7.0 points per year on ADAS-Cog, 3.8 points on MMSE and 3.5 points on IADL Compared to published deterioration rates, patients treated with eptastigmine for two years had a benefit of 6.4 points on ADAS-Cog, 39 points on MMSE and 4.8 points on IADL These benefits translate to about one year difference between eptastigmme-treated patients and placebo-treated patients Our data support the view that AD patients derive long-term benefit from eptastigmine.

AB - The long term effectiveness of choiinesterase inhibitors in Alzheimer's disease (AD) is a matter of controversy To evaluate the potential long-term effects of eptastigmme, a new choiinesterase inhibitor, we evaluated data obtained from the open label extension phase of a 25-week, double-blind, placebo-controlled multicenter study in 320 patients with probable AD. In the double-blind phase of the study, patients received placebo t.i.d. (n=106) or eptastigmine 10 mg t.i.d. (n=105) or eptastigmine 15 mg t i.d. (n=109). At the end of the double-blind phase, patients receiving 15 mg t.i.d. performed significantly better than placebo-treated patients on the ADAS-Cog scale In the open label extension phase, patients received eptastigmine 10 mg t.i.d. Twenty-six patients (lOmales and 16 females) with a mean MMSE score of 20 9 and a mean age of 68 years at baseline, completed two years of treatment. The drug was well tolerated At the end of the two year-treatment they showed a worsening of 76 points on ADAS-Cog, 37 points on MMSE and 2.2 points on Instrumental Activities of Daily Living scale Patients with mild to moderate AD treated with placebo are expected to have a worsening of approximately 7.0 points per year on ADAS-Cog, 3.8 points on MMSE and 3.5 points on IADL Compared to published deterioration rates, patients treated with eptastigmine for two years had a benefit of 6.4 points on ADAS-Cog, 39 points on MMSE and 4.8 points on IADL These benefits translate to about one year difference between eptastigmme-treated patients and placebo-treated patients Our data support the view that AD patients derive long-term benefit from eptastigmine.

UR - http://www.scopus.com/inward/record.url?scp=33746327816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746327816&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33746327816

VL - 18

SP - 29

JO - Italian Journal of Neurological Sciences

JF - Italian Journal of Neurological Sciences

SN - 0392-0461

IS - 4

ER -